Kezar Life Sciences, Inc. announced resingation of Jean-Pierre Sommadossi, Ph.D., Chairman of the Board of Directors with effect from May 11, 2022. In connection with his resignation from the Board, Dr. Sommadossi also resigned from all committees of the Board on which he served, including the Compensation Committee. The decision by Dr. Sommadossi to resign was not the result of any disagreements with the Board or management of the Company.

Following Dr. Sommadossi's resignation, on May 12, 2022, the Board appointed current director Graham Cooper as Chairman of the Board, and in connection with the appointment, the Board granted Mr. Cooper a one-time option to purchase 26,000 shares of the Company's common stock (the “Option”). Subject to Mr. Cooper ' s continued service on the Board, the Option will vest in equal monthly amounts over three years.